羟苯磺酸钙联合雷珠单抗对非缺血型视网膜静脉阻塞患者最佳矫正视力及复发率的影响  

The Effect of Combined Calcium Dobesilate and Ranibizumab on Best-Corrected Visual Acuity and Recurrence Rate in Patients with Nonischemic Retinal Vein Occlusion

作　　者：党文君 DANG Wen-jun(Department of Ophthalmology,Zhumadian City Central Hospital,Zhumadian 463000,China)

机构地区：[1]驻马店市中心医院眼科,河南驻马店463000

出　　处：《实用临床医学(江西)》2025年第1期62-65,88,共5页Practical Clinical Medicine

摘　　要：目的探讨羟苯磺酸钙联合雷珠单抗对非缺血型视网膜静脉阻塞(RVO)患者最佳矫正视力及复发率的影响。方法回顾性分析72例非缺血型RVO患者资料,按不同治疗方案分为对照组(接受雷珠单抗治疗)36例和观察组(接受羟苯磺酸钙+雷珠单抗治疗)36例。比较2组治疗3个月后临床疗效、最佳矫正视力(BCVA)、视网膜电图、黄斑中心凹视网膜厚度(CRT)、眼血流动力学(包括峰值血流速度、平均血流速度、阻力指数和搏动指数)、血管内皮功能[包括内皮素-1(ET-1)、一氧化氮(NO)和血管内皮生长因子(VEGF)]、不良反应(包括食欲减退、眼部异物感和恶心等)发生率及复发率。结果观察组临床总有效率高于对照组(91.67%比69.44%,P<0.05)。治疗后,2组患者CRT、阻力指数、搏动指数、ET-1和VEGF水平均低于治疗前,BCVA、视网膜电图、峰值血流速度、平均血流速度、NO水平均高于治疗前(均P<0.05);与对照组相比,观察组患者治疗后CRT、阻力指数、搏动指数、ET-1和VEGF水平均更低,BCVA和视网膜电图、峰值血流速度、平均血流速度、NO水平均更高(均P<0.001)。2组不良反应发生率及复发率比较,差异无统计学意义(P>0.05)。结论羟苯磺酸钙联合雷珠单抗治疗非缺血型RVO可减轻患者眼底病变程度,提高视力,还可改善眼血流动力学和血管内皮功能,安全性高。Objective To investigate the effects of calcium dobesilate combined with ranibizumab on best-corrected visual acuity(BCVA)and recurrence rates in patients with nonischemic retinal vein occlusion(RVO).Methods A retrospective analysis was conducted on 72 nonischemic RVO patients,who were divided into a control group(ranibizumab monotherapy,n=36)and an observation group(calcium dobesilate plus ranibizumab,n=36).Clinical efficacy,BCVA,electroretinogram parameters,central retinal thickness(CRT),ocular hemodynamics(peak systolic velocity[PSV],mean flow velocity[MFV],resistive index[RI],pulsatility index[PI]),vascular endothelial function(endothelin-1[ET-1],nitric oxide[NO],vascular endothelial growth factor[VEGF]),adverse events(appetite loss,ocular foreign body sensation,nausea),and recurrence rates were compared at 3 months post-treatment.Results The observation group demonstrated higher clinical efficacy(91.67%vs 69.44%,P<0.05).Both groups exhibited reduced levels of CRT,RI,PI,ET-1 and VEGF,with elevated levels of BCVA,electroretinogram amplitudes,PSV,MFV,and NO post-treatment(all P<0.05).Compared to controls,the observation group showed lower levels of CRT,RI,PI,ET-1 and VEGF(all P<0.001),with higher levels of BCVA,electroretinogram amplitudes,PSV,MFV and NO(all P<0.001).No statistically significant differences in adverse events or recurrence rates were observed between both groups(P>0.05).Conclusion The combined administration of calcium dobesilate and ranibizumab can attenuate fundus pathological alterations and enhance visual acuity in nonischemic retinal vein occlusion(RVO),while potentially improving ocular hemodynamic parameters and vascular endothelial function,with positive safety profile.

关 键 词：非缺血型视网膜静脉阻塞 羟苯磺酸钙 雷珠单抗 最佳矫正视力 复发率 

分 类 号：R774.1[医药卫生—眼科]